Outcome of the Board Meeting held on Friday, November 14, 2025, pursuant to Regulations 30, 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.6 pts less than Nifty Microcap 250 and 19.7 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors approved the Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2025, along with a clean (unmodified) Limited Review Report from statutory auditor Mittal & Associates. On a standalone basis, revenue from operations fell to ₹2,698.78 lakhs from ₹3,270.76 lakhs in H1 FY25 (a decline of about 17.5%), while profit after tax dropped to ₹342.99 lakhs (₹3.16 EPS) from ₹525.01 lakhs (₹4.83 EPS). On a consolidated basis, revenue declined to ₹3,092.68 lakhs from ₹3,885.99 lakhs (~20.4% decline) and PAT fell to ₹432.97 lakhs from ₹563.56 lakhs. The auditor also certified that the full IPO proceeds of ₹2,304 lakhs have been fully utilised as per the stated objects, with no balance remaining.
For shareholders, this is a negative result — both top line and bottom line have shrunk by roughly a fifth year-on-year, signalling either pricing pressure or weaker demand in the speciality chemicals business. The clean auditor opinion and fully utilised IPO funds are positives, but the sharp profit compression may weigh on the stock in the near term.